TABLE 1.

Geometric-mean pharmacokinetic data following single doses of caspofungina

Dose (mg)bNo. of subjectsAUC0-∞ (μg · h/ml)C1h (μg/ml)C24h (μg/ml)CLc (ml/min)t1/2βd (h)
568.04 (7.06, 9.17)0.78 (0.71, 0.86)0.10 (0.08, 0.12)10.36 (9.09, 11.81)10.26 ± 2.31
10615.13 (13.33, 17.17)1.60 (1.46, 1.76)0.18 (0.15, 0.21)11.02 (9.71, 12.50)9.56 ± 1.63
20630.97 (27.17, 35.30)3.06 (2.78, 3.37)0.36 (0.30, 0.44)10.77 (9.45, 12.27)10.72 ± 0.73
40655.60 (49.00, 63.10)6.17 (5.61, 6.79)0.57 (0.48, 0.68)11.99 (10.56, 13.61)9.64 ± 0.83
706118.45 (103.92, 135.01)12.04e (10.87, 13.33)1.42 (1.18, 1.71)9.85 (8.64, 11.23)9.29 ± 1.96
1005134.11 (117.78, 152.71)14.03 (12.69, 15.53)1.47 (1.23, 1.76)12.43 (10.91, 14.15)8.61 ± 1.15
  • a Values in parentheses are 90% CIs.

  • b We evaluated doses of 5, 20, and 70 mg in the men in panel A and doses of 10, 40, and 100 mg in the men in panel B. At each dose level, three of nine subjects in each panel received a placebo in a randomized fashion, such that results within panel are partially, but not completely, crossed over.

  • c CL, geometric-mean clearance.

  • d Harmonic mean ± jack-knife standard deviation reported for t1/2β.

  • e The number of C1h obtained was 5 at this dose due to a missing value.